<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003074'>Hyperglycemia</z:hpo>-induced <z:mp ids='MP_0003674'>oxidative stress</z:mp> is detrimental for endothelial cells, contributing to the vascular complications of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> permeability transition pore (<z:chebi fb="0" ids="52242">PTP</z:chebi>) is an <z:mp ids='MP_0003674'>oxidative stress</z:mp>-sensitive channel involved in cell <z:hpo ids='HP_0011420'>death</z:hpo>; therefore, we have examined its potential role in endothelial cells exposed to <z:mp ids='MP_0003674'>oxidative stress</z:mp> or high <z:chebi fb="105" ids="17234">glucose</z:chebi> level </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi>, an antihyperglycemic agent used in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, was also investigated because it inhibits <z:chebi fb="0" ids="52242">PTP</z:chebi> opening in transformed cell lines </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporin A</z:chebi> (CsA), the reference <z:chebi fb="0" ids="52242">PTP</z:chebi> inhibitor, and a therapeutic dose of <z:chebi fb="0" ids="6801">metformin</z:chebi> (100 micromol/l) led to <z:chebi fb="0" ids="52242">PTP</z:chebi> inhibition in permeabilized human microvascular endothelial cells (HMEC-1) </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, exposure of intact HMEC-1 or primary endothelial cells from either human umbilical vein or bovine aorta to the oxidizing agent tert-butylhydroperoxide or to 30 mmol/l <z:chebi fb="105" ids="17234">glucose</z:chebi> triggered <z:chebi fb="0" ids="52242">PTP</z:chebi> opening, <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> decompartmentalization, and cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>CsA or <z:chebi fb="0" ids="6801">metformin</z:chebi> prevented <z:hpo ids='HP_0000001'>all</z:hpo> of these effects </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:chebi fb="11" ids="22586">antioxidant</z:chebi> N-<z:chebi fb="9" ids="46887">acetyl</z:chebi>-l-cysteine also prevented <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that 1) elevated <z:chebi fb="105" ids="17234">glucose</z:chebi> concentration leads to an <z:mp ids='MP_0003674'>oxidative stress</z:mp> that favors <z:chebi fb="0" ids="52242">PTP</z:chebi> opening and subsequent cell <z:hpo ids='HP_0011420'>death</z:hpo> in several endothelial cell types and 2) <z:chebi fb="0" ids="6801">metformin</z:chebi> prevents this <z:chebi fb="0" ids="52242">PTP</z:chebi> opening-related cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>We propose that <z:chebi fb="0" ids="6801">metformin</z:chebi> improves <z:mp ids='MP_0002055'>diabetes</z:mp>-associated <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> both by lowering blood <z:chebi fb="105" ids="17234">glucose</z:chebi> and by its effect on <z:chebi fb="0" ids="52242">PTP</z:chebi> regulation </plain></SENT>
</text></document>